Cost-effectiveness of first-line ribociclib use vs palbociclib in the treatment of postmenopausal women with HR+/HER2− advanced breast cancer: analysis based on final OS results of MONALEESA-2 and PALOMA-2. (November 2022) - Cameron, D.A.; Sharma, V.K.; Biswas, C.; Clarke, C.; Chandiwana, D.; Pathak, P.